ArticleCancer reports (Hoboken, N.J.)2025
Integrative Genomic and Functional Approaches Identify FUOM as a Key Driver and Therapeutic Target in Cervical Cancer.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer remains a global public health challenge, particularly in regions with limited access to screening and vaccination. While high-risk HPV infection is the primary cause, the genetic and molecular mechanisms driving cervical cancer progression are not fully understood.
objectiveThis study integrates Mendelian randomization (MR) and single-cell RNA sequencing (scRNA-seq) to identify causal eQTL-related genes and explore their roles in tumorigenesis. Functional experiments were conducted to validate key findings.
methodsMR analysis identified eQTL-related genes with significant causal associations with cervical cancer. Functional enrichment and Gene Set Variation Analysis (GSVA) revealed their involvement in key pathways. scRNA-seq explored cell-specific expression patterns and immune cell infiltration in the tumor microenvironment (TME). In vitro experiments, including qRT-PCR, siRNA knockdown, migration, proliferation, and colony formation assays, validated the biological roles of pivotal genes.
resultsA total of 307 eQTL-related genes were identified, enriched in pathways such as Th17 cell differentiation, TNF, and IL-17 signaling. scRNA-seq revealed cell-specific expression of key genes, including FUOM, which was elevated in cervical cancer cells. FUOM knockdown significantly reduced cell proliferation (by 37%, p < 0.001), migration (by 43%, p < 0.001), and colony formation (by 62%, p < 0.001). Regulatory analysis identified miRNAs as upstream modulators of these genes.
conclusionThis study identifies FUOM as a novel driver gene in cervical cancer progression and highlights its role in tumorigenesis and immune modulation. These findings provide insights into potential biomarkers and therapeutic targets, offering a foundation for personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.